All articles tagged with #sales guidance
Novo Nordisk's shares dropped 26% after the company lowered its full-year sales and profit forecasts due to weaker growth expectations for its Wegovy obesity drug in the U.S. and announced a new CEO, Maziar Mike Doustdar, following the surprise departure of Lars Fruergaard Jørgensen.
Abbott Laboratories' stock fell nearly 6% after lowering its 2025 sales outlook following a mixed Q2 report, despite beating revenue and earnings estimates; growth in medical devices and established pharmaceuticals was strong, but diagnostics underperformed, leading to a cautious outlook and a premarket decline.
Best Buy has lowered its full-year sales and profit forecasts due to increased costs from tariffs on electronics, which have also impacted quarterly earnings and sales, as the company navigates ongoing trade policy uncertainties and aims to enhance customer experience and operational efficiency.
UiPath's stock plummeted nearly 30% in premarket trading after the company announced the sudden departure of CEO Rob Enslin and provided weak sales guidance for the current quarter, citing a challenging macroeconomic environment and leadership transition. Co-founder Daniel Dines will return as CEO, and the company revised its full-year revenue forecast downward. Investors are watching if the stock can hold above the $14 support level.
Eli Lilly's strong fourth-quarter results and 2024 sales guidance exceeding Wall Street's expectations have led to an increase in the stock's price target by $120, reinforcing its position as the world's most valuable drugmaker.
Starbucks missed Q1 earnings expectations, leading to a cut in full year sales guidance and a decrease in revenue growth projections. Despite the disappointing results, investors remained optimistic, causing shares to rise in after-hours trading. The company attributed the underperformance to challenges in the Middle East and China, where same-store sales fell short of expectations. To address these issues, Starbucks plans to introduce new flavors and drinks, increase investments in technology, and expand its presence in lower tier markets.
DocuSign's stock initially rose 8% but later fell in extended trading after the company reported better-than-expected quarterly results and sales guidance. The software company's net income for the fiscal third quarter was $38.8 million, compared to a net loss of $29.9 million in the same period last year. Revenue increased to $700.4 million from $645.5 million. DocuSign provided fourth-quarter sales guidance of $696 million to $700 million, slightly higher than analysts' expectations. The company aims to expand beyond e-signature into intelligent agreement management.
Paycom Software's stock (PAYC) plummeted by 38.5% after reporting a revenue miss for the third quarter and providing weak sales guidance for 2024. The company attributed the weak results to cannibalization of services revenue and acknowledged the challenges it faces in a competitive human capital management market. Paycom's earnings for Q3 were $1.77 per share, up 39% YoY, with revenue increasing by 22% to $406.3 million. However, the company's outlook for 2024 predicts revenue growth of only 10% to 12%, significantly lower than consensus estimates of 21% growth. The disappointing report also affected shares of Paylocity Holding, Paychex, and Workday.